Sera Prognostics, Inc. (NASDAQ:SERA) Insider Sells $29,850.96 in Stock

Sera Prognostics, Inc. (NASDAQ:SERA) insider Paul Kearney sold 4,078 shares of the firm’s stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $7.32, for a total transaction of $29,850.96. Following the completion of the transaction, the insider now directly owns 176,889 shares in the company, valued at approximately $1,294,827.48. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Sera Prognostics Stock Performance

NASDAQ SERA opened at $6.97 on Thursday. The company has a 50-day simple moving average of $7.40 and a 200 day simple moving average of $7.65. Sera Prognostics, Inc. has a 52-week low of $1.65 and a 52-week high of $12.35. The company has a market capitalization of $232.59 million, a PE ratio of -7.04 and a beta of 1.04.

Sera Prognostics (NASDAQ:SERA) last issued its earnings results on Wednesday, November 6th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.02). The business had revenue of $0.03 million for the quarter, compared to analyst estimates of $0.09 million. During the same quarter last year, the firm earned ($0.23) earnings per share. As a group, analysts forecast that Sera Prognostics, Inc. will post -0.96 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the business. Quest Partners LLC increased its stake in Sera Prognostics by 533.5% in the 3rd quarter. Quest Partners LLC now owns 6,430 shares of the company’s stock worth $50,000 after purchasing an additional 5,415 shares during the period. SG Americas Securities LLC bought a new stake in shares of Sera Prognostics in the 3rd quarter worth approximately $78,000. The Manufacturers Life Insurance Company bought a new position in shares of Sera Prognostics in the second quarter worth approximately $68,000. Prime Capital Investment Advisors LLC bought a new stake in Sera Prognostics in the 3rd quarter worth about $104,000. Finally, MetLife Investment Management LLC increased its position in shares of Sera Prognostics by 129.1% during the 3rd quarter. MetLife Investment Management LLC now owns 17,254 shares of the company’s stock valued at $135,000 after purchasing an additional 9,722 shares during the last quarter. Hedge funds and other institutional investors own 54.64% of the company’s stock.

About Sera Prognostics

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.